Cloudbreak Pharma

We are a clinical stage global biotechnology company developing ophthalmic drugs for chronic eye diseases which are often with few treatment options. Our broad pipeline was developed by in-house scientists with the experience and expertise to identify new targeted mechanisms of action and craft formulations that amenable to topical ocular delivery. Our deep understanding of ophthalmic disease pathogenesis and extensive scientific know-how led us to our lead pipeline candidate, CBT-001 an investigational eye drop treatment with the potential to slow or stop progression of pterygium, a highly underdiagnosed and undertreated disease with no approved drug therapy

Drug development and clinical trials

Cloudbreak pharma operates in the Biotechnology industry.

Cloudbreak pharma's revenue is 11m - 100m

Cloudbreak pharma has 11 - 50 employees.